{"url_path":"/sec/crvo/8-k/2026-06-22/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1053691/0001437749-26-021309-index.html","accession_number":"0001437749-26-021309","cik":"0001053691","ticker":"CRVO","issuer_name":"CervoMed Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1053691/0001437749-26-021309-index.html","primary_entity_key":"0001053691","primary_entity_name":"CervoMed Inc."},"word_count":168,"has_tables":true,"body_markdown":"**Item 7.01. Regulation FD Disclosure.**\n\n \n\nOn June 22, 2026, CervoMed Inc. (the “Company”) issued a press release announcing the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,500,000 shares of the Company’s common stock at a purchase price of $4.00 per share of common stock (the “Offering”).\n\n \n\nThe press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information in or incorporated by reference into this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing."}